[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-stem-cell-mobilization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-stem-cell-mobilization":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100556059","phase-3-comparison-study-of-eap-and-disease-specific-chemotherapy-regimens-in-hematopoietic-stem-cell-mobilization-for-lymphoma-100556059",false,"NCT06520163","Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety of Etoposide, Cytarabine, and PEG-rhG-CSF Combination Therapy vs. Disease-Specific Chemotherapy for Hematopoietic Stem Cell Mobilization in Lymphoma","Inclusion Criteria:\n\n* Diagnosed with non-Hodgkin's lymphoma before enrollment.\n* Indication for autologous stem cell transplantation (ASCT).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0\\~1.\n* Achieved complete remission after multiple courses of chemotherapy.\n* Life expectancy ≥ 3 months.\n* Subjects must be able to understand the protocol and sign the informed consent.\n\nExclusion Criteria:\n\n* Cardiac function class II or higher or cardiac ejection fraction \\\u003C 40%.\n* Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN).\n* Serum creatinine clearance rate ≤ 50%.\n* Patients with active infection.\n* History of prior hematopoietic stem cell mobilization.","ALL","18 Years","75 Years",{"count":20,"type":21},99,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\\^6\u002Fkg).",[27,28],"Non-Hodgkin's Lymphoma","Hematopoietic Stem Cell Mobilization",[27,30,31,32],"Disease-Specific Chemotherapy","Hematopoietic stem cell mobilization","Etoposide, Cytarabine Combined with PEG-rhG-CSF","RECRUITING","2025-11-27",{"date":36,"type":37},"2025-12-04","ACTUAL",{"date":39,"type":37},"2024-08-01",{"date":41,"type":21},"2026-08",{"name":43,"class":44},"The Affiliated People's Hospital of Ningbo University","OTHER_GOV",17,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100589549","clinical-study-of-rhtpo-in-hematopoietic-stem-cell-mobilization-for-autologous-transplantation-in-acute-leukemia-100589549","NCT06955858","Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia","Recombinant Human Thrombopoietin for Autologous Hematopoietic Stem Cell Mobilization in Acute Leukemia: A Single-Arm Prospective Study","Inclusion Criteria:\n\n1. Age 18～65 years, regardless of gender.\n2. Histopathologically confirmed acute leukemia with immunohistochemical validation\n3. Sustained complete hematologic remission with documented minimal residual disease (MRD) negativity.\n4. Eastern Cooperative Oncology Group (ECOG) performance status smaller than 2 and a life expectancy of more than 6 months\n5. No active infectious disease; no severe organ failure.\n6. Willingness to participate with written informed consent for study enrollment.\n\nExclusion Criteria:\n\n1. Liver dysfunction (alanine aminotransferase or bilirubin greater than two times the normal upper limit).\n2. Renal dysfunction (creatinine or urea higher than 1.5 times the normal upper limit).\n3. Any disease that could put patients at high risk, including but not limited to unstable cardiac disease, uncontrolled atrial fibrillation or hypertension, severe diabetic retinopathy\n4. rhTPO aller- gies.\n5. Severe prior thrombosis-event.\n6. History of other malignancy, unless cured for more than 3 years\n7. Pregnant or lactating women\n8. Severe infectious disease (uncured tuberculosis, pulmonary aspergillosis)\n9. Epilepsia, dementia or any mental disease requiring treatment.\n10. Other conditions deemed inappropriate for study participation by the investigator.","65 Years",{"count":55,"type":21},60,[57],"NA","Evaluation of the efficacy and safety of recombinant human thrombopoietin (rhTPO) at 300 U\u002Fkg\u002Fday for hematopoietic stem cell mobilization in autologous transplantation among acute leukemia patients",[28],[61],"Recombinant Human Thrombopoietin","NOT_YET_RECRUITING","2025-04-30",{"date":65,"type":37},"2025-05-02",{"date":67,"type":21},"2025-05-30",{"date":69,"type":21},"2026-12-30",{"name":71,"class":72},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100556060","phase-3-comparison-study-of-eap-and-cg-regimens-for-mobilizing-hematopoietic-stem-cells-in-multiple-myeloma-patients-100556060","NCT06520176","Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","A Prospective, Multicenter, Randomized Controlled Study of Etoposide, Cytarabine Combined With Pegfilgrastim vs. Cyclophosphamide Combined With G-CSF for Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma Patients","Inclusion Criteria:\n\n* 1\\. Patients newly diagnosed as multiple myeloma.\n* 2\\. Indication for ASCT.\n* 3\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0\\~1.\n* 4\\. Life expectancy ≥ 3 months.\n* 5\\. Subjects must be able to understand the protocol and sign the informed consent.\n\nExclusion Criteria:\n\n* 1\\. Cardiac function class II or higher or cardiac ejection fraction \\\u003C40%.\n* 2\\. Serum direct bilirubin (DBIL)\\>2× upper limit of normal (ULN).\n* 3\\. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3× ULN.\n* 4\\. Serum creatinine clearance rate≤30%.\n* 5\\. Patients with active infection.\n* 6\\. Previously received hematopoietic stem cell mobilization.",{"count":20,"type":21},[24],"This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.",[85,28],"Multiple Myeloma",[85,87,88,89,28],"Etoposide","Cytarabine","PEG-rhG-CSF","2024-07-20",{"date":92,"type":37},"2024-07-25",{"date":94,"type":21},"2024-08",{"date":96,"type":21},"2026-12",{"name":43,"class":44},16]